First recombinant von Willebrand Factor approved by FDA

The United States Food and Drug Administration (FDA) has approved Vonvendi, a recombinant von Willebrand Factor manufactured by Baxalta.

The product is approved for on-demand treatment and controlling bleeding in patients with von Willebrand disease. The product will become available in the US in 2016 and Baxalta plans to apply for approval in Europe and other markets in 2017. For more information click here.